PeptideReference
Back to Peptide Library

PEG-MGF

Pegylated Mechano Growth Factor (PEGylated IGF-1Ec E-domain peptide). Synonyms: PEG-MGF, Pegylated MGF, PEGylated Mechano-Growth Factor, MECHA-FACTO (brand name, DenikPharm).

Preclinical OnlyFDA Category 2

FDA has identified this as a Category 2 bulk drug substance with significant safety risks for compounding. No human exposure data exists.

A modified form of a natural muscle-repair signal the body produces after exercise or injury, chemically altered to last longer in the body. It has shown the ability to activate muscle repair cells in animal studies, but no human clinical trials exist.

11 studiesUpdated 2026-03-13Intramuscular injection (IM) -- commonly used for localized effect in target muscle · Subcutaneous injection (SC) -- commonly used for systemic exposure

This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.

Clinical bottom linePreclinical

PEG-MGF is preclinical or hypothesis-only.

FDA has identified this as a Category 2 bulk drug substance with significant safety risks for compounding. No human exposure data exists.

Safety Summary

CRITICAL CAVEAT: All side effect frequency estimates for PEG-MGF are from vendor/product summaries, community/anecdotal reports, and extrapolation from related PEGylated compounds -- NOT from controlled human clinical trials, which do not exist for PEG-MGF. No reproducible peer-reviewed body of evidence documents frequent or clearly attributable serious adverse events (SAEs) for PEG-MGF in humans. FDA FAERS and EMA EudraVigilance public databases returned no identifiable spontaneous-report signals for PEG-MGF as of March 2026. Class-level immunogenicity risks are salient: anti-PEG antibodies (IgM/IgG) can be pre-existing or treatment-induced, may cause accelerated blood clearance (ABC) and loss of efficacy, and can predispose to hypersensitivity or CARPA reactions PMC12388889. Theoretical long-term risks include the promotion of undetected tumor growth due to the potent proliferative mechanism. Long-term human safety data are effectively absent. Unregulated sourcing and variable product purity in research/consumer markets create ongoing safety concerns.

Clinical check-in

If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.

See cited studies on this page (11)

Cited sources

Every claim on this page links to one of the 11 sources below. Identifiers are PubMed (PMID), ClinicalTrials.gov (NCT), or DOI; click through to the source of record before acting on a claim.

  1. 1doi:10.3389/fendo.2012.00127DOI
  2. 2doi:10.1371/journal.pone.0150453DOI
  3. 3doi:10.1007/s10544-014-9885-xDOI
  4. 4doi:10.1016/j.biomaterials.2014.12.050DOI
  5. 5doi:10.1186/s12858-015-0031-zDOI
  6. 6PMID 21354439PubMed
  7. 7PMID 28683812PubMed
  8. 8PMID 17581790PubMed
  9. 9Mechano growth factor attenuates mechanical overload-induced nucleus pulposus cell apoptosis through inhibiting the p38 MAPK pathwayReference
  10. 10MGF overexpression modulates inflammatory cell dynamics during muscle repairReference
  11. 11Mechano growth factor E peptide promotes osteoblasts proliferation and bone-defect healing in rabbitsReference